| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:266.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
From the Division of Cardiology, Department of Medicine, Tokai University School of Medicine, Kanagawa (S.G., N.T., S.H.); the Department of Laboratory Medicine, Tokyo Medical University, Tokyo (M.A.); and the Department of Hematology and Oncology, Clinical Sciences for Pathological Organs, Graduate School of Medicine, Kyoto University, Kyoto (K.K., H.T.), Japan.
Correspondence to Hiroshi Takayama, MD, Department of Hematology and Oncology, Clinical Sciences for Pathological Organs, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto 606-8507, Japan. E-mail hiro{at}kuhp.kyoto-u.ac.jp; or Shinya Goto, MD, Division of Cardiology, Department of Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. E-mail shinichi@is.icc.u-tokai.ac.jp
| Abstract |
|---|
|
|
|---|
Methods and Results Whole blood obtained from 2 patients with GP VIdeficient platelets and the effects of the Fab of antiGP VI antibody (Fab/antiGP VI) were tested. Blood containing platelets rendered fluorescent by mepacrine was perfused on immobilized type I collagen or vWF under controlled wall shear rate. Platelet adhesion and thrombus formation were detected by epifluorescent videomicroscopy. The percentage of surface coverage by the platelets was calculated. Fc receptor
-chain and spleen tyrosine kinase (Syk) were immunoprecipitated from the lysate of platelets stimulated by vWF plus ristocetin and then analyzed by antiphosphotyrosine immunoblotting. No platelet attachment was seen on the surface of collagen even after 9 minutes of perfusion of blood at relatively low (100 s-1) or high (1500 s-1) wall shear rate, either in the case of blood containing GP VIdeficient platelets or in the presence of Fab/antiGP VI, whereas significant platelet thrombus formation was noted after control blood perfusion. Such interference with the actions of GP VI also reduced firm platelet adhesion on immobilized vWF. vWF-induced tyrosine phosphorylation of GP VIassociated Fc receptor
-chain followed by Syk activation occurred in normal platelets, but little activation of Syk occurred in GP VIdeficient platelets.
Conclusions GP VI plays crucial roles in platelet thrombus formation on the surface of collagen under flow conditions in humans and is also involved in the process of firm platelet adhesion on the surface of vWF.
Key Words: platelets von Willebrand factor glycoproteins thrombosis
| Introduction |
|---|
|
|
|---|
IIbß3 (GP IIb/IIIa), are intimately involved in occlusive thrombus formation at the site of endothelial damage caused by interventional treatments, such as PTCA.5,6 Because initial platelet contact is thought to be mediated by platelet interaction with components of the subendothelial matrix, including collagen7 and immobilized and self-associated soluble von Willebrand factor (vWF),8,9 at the site of endothelial damage, this interaction could provide a suitable target for specific antiplatelet agents. Recently, Nieswandt et al10 performed functional studies using ß1-null or GP VIdeficient mouse platelets under flow conditions and reported that GP VI rather than integrin
2ß3 plays a more important role in platelet interaction with immobilized collagen under various flow conditions. They further proposed, on the basis of a revised model, that GP VI binding to collagen after GP Ib
vWF interactions is an essential prerequisite for upregulation of the activity of integrins such as
2ß3 and
IIbß3, which mediate firm platelet adhesion that is followed by platelet thrombus formation. In the present study, we investigated the role of GP VI in platelet thrombus formation on the collagen surface under flow conditions in humans and further attempted to clarify the involvement of GP VI in platelet adhesion on the immobilized vWF surface in the absence of collagen.
| Methods |
|---|
|
|
|---|
Sample Preparation
Blood was obtained from 2 patients whose platelets lacked GP VI [one followed up at Kyoto University Hospital (Kyoto patient14) and the other at Tokyo Medical University Hospital (Tokyo patient16)], as well as from 2 normal volunteers, a 40-year-old man and a 30-year-old woman, at the same time and by the same method. The blood was then anticoagulated by the addition of 1/10 volume of 1 mmol/L of a specific antithrombin agent, argatroban (Mitsubishi Kagaku, Inc), and used for the following experiments, in the presence of physiological concentrations of divalent cations.17 Plasma-free reconstituted blood was obtained from the Tokyo patient and the 40-year-old male control subject as described previously, with slight modification.9 Briefly, blood cells were resuspended in modified HEPESTyrodes solution (mmol/L: 10 HEPES, 140 NaCl, 27 KCl, 0.4 NaH2PO4, 10 NaHCO3, 5 dextrose, and 1 CaCl2, and 5 mg/mL BSA, pH 7.4) after the washing procedures.9 These blood donors had not taken any drugs known to interfere with platelet functions, such as NSAIDs, for at least 4 weeks before the study.
Platelets were rendered fluorescent by the addition of mepacrine at a final concentration of 10 µmol/L (Sigma). Although mepacrine is known to affect platelet function through inhibition of phospholipid hydrolysis,18 previous studies have shown that it does not affect platelet activation and thrombus formation on the surface of collagen and immobilized vWF under flow conditions at the dose we used.8,9,1921
Preparation of the Flow Chamber System and Platelet Thrombus Visualization by Epifluorescent Videomicroscopy
Acid-insoluble fibrillar type I collagen from bovine Achilles tendon (Sigma) was immobilized on a glass coverslip (Corning, Inc; 24x50 mm) in a parallel plate flow chamber, as described previously.1921 Similarly, human vWF purified from the factor VIII/vWF concentrate of Fhandi was also immobilized on a glass coverslip in the chamber as previously reported.22 The blood samples were then introduced into the chamber with a syringe pump (Holliston, MA 01746, Harvard Apparatus Co) at a constant flow rate to achieve the intended wall shear rates on the surface of collagen or vWF.
Platelet thrombi forming on the surface of collagen or vWF were visualized with an inverted-stage epifluorescence videomicroscope system equipped with a 480-nm excitation light source (DM IRB, 1RB-FLUO, Leica) as described previously.21 The microscopic images were digitized online with a photosensitive color CCD camera (L-600, Leica) and stored as digital images in a personal computer (Power Macintosh G3, Apple). To quantify the percentage of surface coverage by the platelets, the digital color images were converted into black-and-white images with NIH Image software (public domain software by Dr Wayne Rasband, National Institutes of Health, version 1.62), and the percent area covered by the platelets was calculated.
The effect of GP VI deficiency on platelet-vWF surface interaction was qualitatively demonstrated by overlaying 30 consecutive frames of the video images (corresponding to 1 second) so that firmly attached platelets that did not move appeared as thick images and moving (eg, rolling) platelets, which appeared in only some of the frames, appeared as thinner images. The movement of every single platelet appearing in consecutive image frames was quantified. The effect of GP VI deficiency on platelet-vWF surface interaction was also tested in plasma-free reconstituted blood.
Immunoprecipitation and Immunoblotting
Washed platelets (1.0x109 cells/mL) prepared as previously described23 were preincubated with or without 100 µg/mL Fab/antiGP VI for 3 minutes and stimulated with 10 µg/mL vWF in the presence of 1 mg/mL ristocetin for the indicated times at 37°C in an aggregometer under continuous stirring. Unstimulated or stimulated platelets were lysed in an ice-cold lysis buffer, and immunoprecipitation of each specified protein, followed by immunoblot analysis, was performed as described previously.24
| Results |
|---|
|
|
|---|
|
|
|
Platelet Thrombus Formation on Immobilized vWF
Platelet thrombus formation on immobilized vWF was also inhibited, but not completely, after perfusion of blood containing platelets lacking GP VI (Figure 4). The percentage surface coverage by platelets was inhibited by >50% after perfusion of blood containing platelets lacking GP VI. Involvement of GP VI in platelet attachment on the surface of vWF was also demonstrated by the results obtained with blood containing Fab/antiGP VI (Figure 5).
|
|
To understand the role of GP VI in platelet attachment on the surface of vWF in the absence of collagen under flow conditions, platelet movement on the surface of immobilized vWF was also investigated. Most of the control platelets became firmly attached to the vWF surface without exhibiting continuous movement, whereas the majority of GP VIdeficient platelets, especially under the relatively high shear rate of 1500 s-1, exhibited continuous movements on the vWF surface (Figure 6). Control platelets, once they adhered to the vWF surface, moved only 0.25±0.71 µm (mean±SD) during a period of 1 second, whereas GP VIdeficient platelets moved 6.18±6.40 µm (P=0.0000022). Virtually no platelet interaction with the vWF surface could be seen in GP VIdeficient platelets, whereas stable platelet adhesion on the vWF surface could still be seen in the control platelets in the absence of plasma proteins (Figure 7).
|
|
vWF Stimulation Accompanies Tyrosine Phosphorylation of the Fc Receptor
-Chain Associated with GP VI
It has been well established that GP VI is coupled to Fc receptor
-chain (FcR
) and signals tyrosine phosphorylation of FcR
, followed by activation of spleen tyrosine kinase (Syk).24,25 Therefore, we examined biochemically whether GP VIassociated FcR
was tyrosine-phosphorylated in platelets stimulated by vWF. FcR
was immunoprecipitated from the lysate of washed platelets stimulated by vWF plus ristocetin in the absence or presence of Fab/antiGP VI and was analyzed by antiphosphotyrosine immunoblotting. As shown in Figure 8A, stimulation of platelets with vWF plus ristocetin resulted in tyrosine phosphorylation of FcR
, but much less in the presence of Fab/antiGP VI. Reprobing of the immunoblot with antiGP VI antibody confirmed that the tyrosine-phosphorylated FcR
was associated with GP VI.
|
The degree of tyrosine phosphorylation of Syk was compared between vWF plus ristocetin-stimulated normal and GP VIdeficient platelets and also between similarly stimulated normal platelets in the absence and presence of Fab/antiGP VI. The results revealed that tyrosine phosphorylation of Syk in GP VIdeficient or Fab/antiGP VIpretreated normal platelets stimulated by vWF plus ristocetin was much weaker than that in normal platelets similarly stimulated by the same substances (Figure 8B).
| Discussion |
|---|
|
|
|---|
vWF mediates initial tethering at relatively high shear rates,8,26 followed by
2ß1-collagen27 and
IIbß3-vWFmediated firm attachment,8,28 which arrests platelets and enables collagen to interact with GP VI, resulting in platelet activation and thrombus formation.10,2729 Recently, this concept was challenged by Nieswandt et al,10 who showed complete loss of attachment of mouse platelets to the surface of immobilized collagen under flow conditions in the absence of GP VI. Because species-specific differences cannot be ruled out in their study, we first attempted to test the behavior of human platelets deficient in GP VI on immobilized collagen surface under flow conditions. Our results revealed that platelet attachment on the surface of collagen was completely inhibited in the presence of GP VI deficiency and also by the addition of Fab/antiGP VI, corroborating the results of Nieswandt et al10 obtained with mouse platelets.
Because previous studies have suggested a crucial role for the interaction between vWF bound to collagen and its receptor GP Ib
on the initial tethering of platelets under high shear rates,19,26,29 we were further prompted to investigate whether interference with GP VI function would affect platelet thrombus formation on immobilized vWF in the absence of collagen under flow conditions. Surprisingly, the results showed that firm platelet attachment and subsequent thrombus formation on immobilized vWF in the absence of collagen were also inhibited in the presence of GP VI deficiency and Fab/antiGP VI. This suggested the involvement of GP VI, not only in collagen-mediated but also in the vWF-mediated process of platelet thrombus formation. Moreover, our results showing complete loss of platelet-vWF interaction with GP VIdeficient platelets suggest the crucial role of GP VI even in transient platelet-vWF interaction, which is presumably mediated exclusively by vWFGP Ib
interaction.26 These results cannot be explained by the revised model proposed by Nieswandt et al.10 However, the question arises as to how the GP VI/FcR
complex is involved in vWF-mediated thrombus formation under flow conditions. Two groups have recently reported that FcR
was tyrosine-phosphorylated when platelets were stimulated by vWFGP Ib
interaction induced by ristocetin or botrocetin.30,31 Because we previously suggested that FcR
was intimately associated with GP VI in human platelets,25 their studies also favor the possibility that the GP VI/FcR
complex is activated in response to vWFGP Ib
interaction. In this study, we have shown the occurrence of tyrosine phosphorylation of GP VIassociated FcR
, followed by Syk activation in association with vWFGP Ib
interaction induced by ristocetin. Thus, our data from the present study support the possibility of involvement of the GP VI/FcR
complex pathway in the process of platelet activation, leading to firm platelet adhesion on the surface of vWF through activation of
IIbß3 initiated by vWFGP Ib
interaction but not by GP VIcollagen interaction. It is important to note, however, that the inhibitory effects of interference with GP VI function on platelet attachment on immobilized vWF were less significant than those observed on collagen surface, especially in the presence of plasma proteins. This suggests that the activation of the GP VI/FcR
complex pathway during vWFGP Ib
interaction is not an absolute requirement for subsequent thrombus formation on immobilized vWF and may suggest the possibility of the existence of GP VI/FcR
complexindependent mechanisms for the activation of
IIbß3 by vWFGP Ib
interaction. Another important question is how the GP VI/FcR
complex is activated during vWFGP Ib
interaction in the absence of collagen. Studies are currently under way to resolve these remaining questions.
Because GP VI appears to possess more profound roles in platelet thrombus formation under flow conditions than previously thought, one would consider that antiplatelet agents targeting GP VI would be attractive antiplatelet agents to inhibit platelet thrombus formation at the site of the exposed subendothelial matrix in the event of atheroma rupture in coronary arteries. A recent report of the existence of a relationship between genetic polymorphism of GP VI and the onset of myocardial infarction lends support to this notion.32 Our present findings should motivate researchers to develop an antiGP VI agent to control such clinical events.
In conclusion, we have shown that GP VI plays a crucial role in platelet thrombus formation on the surface of collagen under flow conditions in humans. Furthermore, GP VI is also involved in the process of firm platelet adhesion to the surface of immobilized vWF in the absence of collagen.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received December 12, 2001; revision received April 19, 2002; accepted April 22, 2002.
| References |
|---|
|
|
|---|
2. Weiss HJ. Platelet physiology and abnormalities of platelet function, I. N Engl J Med. 1975; 293: 531541.[Medline] [Order article via Infotrieve]
3. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes, I. N Engl J Med. 1992; 326: 242250.[Medline] [Order article via Infotrieve]
4. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes, II. N Engl J Med. 1992; 326: 310318.[Medline] [Order article via Infotrieve]
5. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. 2000; 284: 15491558.
6. Topol EJ, Byzova TV, Plow EF. Platelet GP IIb-IIIa blockers. Lancet. 1999; 353: 227231.[CrossRef][Medline] [Order article via Infotrieve]
7. Baumgartner HR. Platelet interaction with collagen fibrils in flowing blood, I: reaction of human platelets with alpha chymotrypsin-digested subendothelium. Thromb Haemost. 1977; 37: 116.[Medline] [Order article via Infotrieve]
8. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996; 84: 289297.[CrossRef][Medline] [Order article via Infotrieve]
9. Savage B, Sixma JJ, Ruggeri ZM. Functional self-association of von Willebrand factor during platelet adhesion under flow. Proc Natl Acad Sci U S A. 2002; 99: 425430.
10. Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not
2ß1 integrin is essential for platelet interaction with collagen. EMBO J. 2001; 20: 21202130.[CrossRef][Medline]
[Order article via Infotrieve]
11. Polgar J, Clemetson JM, Kehrel BE, et al. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J Biol Chem. 1997; 272: 1357613583.
12. Morton LF, Hargreaves PG, Farndale RW, et al. Integrin
2ß1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for
2ß1-independent platelet reactivity. Biochem J. 1995; 306: 337344.[Medline]
[Order article via Infotrieve]
13. Nakamura T, Jamieson GA, Okuma M, et al. Platelet adhesion to native type I collagen fibrils: role of GPVI in divalent cation-dependent and -independent adhesion and thromboxane A2 generation. J Biol Chem. 1998; 273: 43384344.
14. Sugiyama T, Okuma M, Ushikubi F, et al. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood. 1987; 69: 17121720.
15. Kehrel B, Wierwille S, Clemetson KJ, et al. Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood. 1998; 91: 491499.
16. Arai M, Yamamoto N, Moroi M, et al. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br J Haematol. 1995; 89: 124130.[Medline] [Order article via Infotrieve]
17. Tsuji S, Sugimoto M, Miyata S, et al. Real-time analysis of mural thrombus formation in various platelet aggregation disorders: distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood. 1999; 94: 968975.
18. Winocour PD, Kinlough-Rathbone RL, Mustard JF. The effect of phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface. Thromb Haemost. 1981; 45: 257262.[Medline] [Order article via Infotrieve]
19. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998; 94: 657666.[CrossRef][Medline] [Order article via Infotrieve]
20. Goto S, Ikeda Y, Saldivar E, et al. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest. 1998; 101: 479486.[Medline] [Order article via Infotrieve]
21. Eto K, Goto S, Shimazaki T, et al. Two distinct mechanisms are involved in stent thrombosis under flow conditions. Platelets. 2001; 12: 228235.[CrossRef][Medline] [Order article via Infotrieve]
22. Miyata S, Ruggeri ZM. Distinct structural attributes regulating von Willebrand factor A1 domain interaction with platelet glycoprotein Ib
under flow. J Biol Chem. 1999; 274: 65866593.
23. Takayama H, Nakamura T, Yanagi S, et al. Ionophore A23187-induced protein-tyrosine phosphorylation of human platelets: possible synergism between Ca2+ mobilization and protein kinase C activation. Biochem Biophys Res Commun. 1991; 174: 922927.[CrossRef][Medline] [Order article via Infotrieve]
24. Ezumi Y, Shindoh K, Tsuji M, et al. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor
chain complex on human platelets. J Exp Med. 1998; 188: 267276.
25. Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor
-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem. 1997; 272: 2352823531.
26. Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood. 1999; 94: 172178.
27. Sixma JJ, van Zanten GH, Huizinga EG, et al. Platelet adhesion to collagen: an update. Thromb Haemost. 1997; 78: 434438.[Medline] [Order article via Infotrieve]
28. Moroi M, Jung SM, Shimmyozu K, et al. Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion. Blood. 1996; 88: 20812092.
29. Moroi M, Jung SM, Nomura S, et al. Analysis of the involvement of the von Willebrand factor-glycoprotein Ib interaction in platelet adhesion to a collagen-coated surface under flow conditions. Blood. 1997; 90: 44134424.
30. Wu Y, Suzuki-Inoue K, Satoh K, et al. Role of Fc receptor
-chain in platelet glycoprotein Ib-mediated signaling. Blood. 2001; 97: 38363845.
31. Falati S, Edmead CE, Poole AW. Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor
-chain, Fyn, and Lyn to activate human platelets. Blood. 1999; 94: 16481656.
32. Croft SA, Samani NJ, Teare MD, et al. Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation. 2001; 104: 14591463.
This article has been cited by other articles:
![]() |
R. K. Andrews, D. Karunakaran, E. E. Gardiner, and M. C. Berndt Platelet Receptor Proteolysis: A Mechanism for Downregulating Platelet Reactivity Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1511 - 1520. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kleinschnitz, M. Pozgajova, M. Pham, M. Bendszus, B. Nieswandt, and G. Stoll Targeting Platelets in Acute Experimental Stroke: Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding Circulation, May 1, 2007; 115(17): 2323 - 2330. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Goto, N. Tamura, H. Ishida, and Z. M. Ruggeri Dependence of Platelet Thrombus Stability on Sustained Glycoprotein IIb/IIIa Activation Through Adenosine 5'-Diphosphate Receptor Stimulation and Cyclic Calcium Signaling J. Am. Coll. Cardiol., January 3, 2006; 47(1): 155 - 162. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Sarratt, H. Chen, M. M. Zutter, S. A. Santoro, D. A. Hammer, and M. L. Kahn GPVI and {alpha}2{beta}1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow Blood, August 15, 2005; 106(4): 1268 - 1277. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mazharian, S. Roger, P. Maurice, E. Berrou, M. R. Popoff, M. F. Hoylaerts, F. Fauvel-Lafeve, A. Bonnefoy, and M. Bryckaert Differential Involvement of ERK2 and p38 in Platelet Adhesion to Collagen J. Biol. Chem., July 15, 2005; 280(28): 26002 - 26010. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gruner, M. Prostredna, M. Koch, Y. Miura, V. Schulte, S. M. Jung, M. Moroi, and B. Nieswandt Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice Blood, February 15, 2005; 105(4): 1492 - 1499. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Matsuno, H. Tokuda, A. Ishisaki, Y. Zhou, Y. Kitajima, and O. Kozawa P2Y12 Receptors Play a Significant Role in the Development of Platelet Microaggregation in Patients with Diabetes J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 920 - 927. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Stephens, Y. Yan, M. Jandrot-Perrus, J.-L. Villeval, K. J. Clemetson, and D. R. Phillips Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen Blood, January 1, 2005; 105(1): 186 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Goto Propagation of Arterial Thrombi: Local and Remote Contributory Factors Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2207 - 2208. [Full Text] [PDF] |
||||
![]() |
C. Lecut, A. Schoolmeester, M. J.E. Kuijpers, J. L.V. Broers, M. A.M.J. van Zandvoort, K. Vanhoorelbeke, H. Deckmyn, M. Jandrot-Perrus, and J. W.M. Heemskerk Principal Role of Glycoprotein VI in {alpha}2{beta}1 and {alpha}IIb{beta}3 Activation During Collagen-Induced Thrombus Formation Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1727 - 1733. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Goto, N. Tamura, and H. Ishida Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions J. Am. Coll. Cardiol., July 21, 2004; 44(2): 316 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. E. Kuijpers, V. Schulte, C. Oury, T. Lindhout, J. Broers, M. F. Hoylaerts, B. Nieswandt, and J. W. M. Heemskerk Facilitating roles of murine platelet glycoprotein Ib and {alpha}IIb{beta}3 in phosphatidylserine exposure during vWF-collagen-induced thrombus formation J. Physiol., July 15, 2004; 558(2): 403 - 415. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R.-M. Siljander, I. C. A. Munnix, P. A. Smethurst, H. Deckmyn, T. Lindhout, W. H. Ouwehand, R. W. Farndale, and J. W. M. Heemskerk Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood Blood, February 15, 2004; 103(4): 1333 - 1341. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Smethurst, L. Joutsi-Korhonen, M. N. O'Connor, E. Wilson, N. S. Jennings, S. F. Garner, Y. Zhang, C. G. Knight, T. R. Dafforn, A. Buckle, et al. Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody Blood, February 1, 2004; 103(3): 903 - 911. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. He, L. K. Pappan, D. G. Grenache, Z. Li, D. M. Tollefsen, S. A. Santoro, and M. M. Zutter The contributions of the {alpha}2{beta}1 integrin to vascular thrombosis in vivo Blood, November 15, 2003; 102(10): 3652 - 3657. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Albes, I. M. Stohr, M. Kaluza, A. Siegemund, D. Schmidt, R. Vollandt, and T. Wahlers Physiological coagulation can be maintained in extracorporeal circulation by means of shed blood separation and coating J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1504 - 1512. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Best, Y. A. Senis, G. E. Jarvis, H. J. Eagleton, D. J. Roberts, T. Saito, S. M. Jung, M. Moroi, P. Harrison, F. R. Green, et al. GPVI levels in platelets: relationship to platelet function at high shear Blood, October 15, 2003; 102(8): 2811 - 2818. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kato, T. Kanaji, S. Russell, T. J. Kunicki, K. Furihata, S. Kanaji, P. Marchese, A. Reininger, Z. M. Ruggeri, and J. Ware The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion Blood, September 1, 2003; 102(5): 1701 - 1707. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Nieswandt and S. P. Watson Platelet-collagen interaction: is GPVI the central receptor? Blood, July 15, 2003; 102(2): 449 - 461. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Romijn, E. Westein, B. Bouma, M. E. Schiphorst, J. J. Sixma, P. J. Lenting, and E. G. Huizinga Mapping the Collagen-binding Site in the von Willebrand Factor-A3 Domain J. Biol. Chem., April 18, 2003; 278(17): 15035 - 15039. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Berndt Induction of Platelet-Endothelial Interactions in Postcapillary Venules in Hypercholesterolemia: Critical Role of P-Selectin Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 525 - 527. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |